Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.7%

1 terminated out of 13 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

69%

9 trials in Phase 3/4

Results Transparency

17%

2 of 12 completed with results

Key Signals

2 with results92% success

Data Visualizations

Phase Distribution

11Total
P 1 (1)
P 2 (1)
P 3 (8)
P 4 (1)

Trial Status

Completed12
Terminated1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04573569CompletedPrimary

Neural Correlates of Cognition and Mood

NCT01002820Phase 2CompletedPrimary

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

NCT03156439Phase 1CompletedPrimary

Bioavailability, Safety, and Tolerability of BIS-001 ER

NCT01128712Phase 4TerminatedPrimary

Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin

NCT00319501Phase 3Completed

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

NCT00991757Phase 3Completed

An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.

NCT00744731Phase 3Completed

An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures

NCT00740623Phase 3Completed

A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.

NCT00425282Phase 3Completed

A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

NCT00433667Phase 3Completed

A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

NCT00056576Phase 3CompletedPrimary

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

NCT00001489Completed

Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism

NCT00143143Phase 3Completed

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Showing all 13 trials

Research Network

Activity Timeline